ASX Cannabis Stocks Face Margin Pressure as Australia Market Matures

Script Growth Decelerates

Prescription volume growth slowed to single digits in Q1 2026 after years of triple-digit expansion. The Therapeutic Goods Administration reported 215,000 active medicinal cannabis prescriptions in March 2026, up 8% year-over-year but down from 47% growth in the prior-year period. The deceleration signals market saturation in early-adopter patient cohorts.

ASX-listed cultivators including Cann Group (ASX:CAN) and Little Green Pharma (ASX:LGP) have cited the slowdown in recent earnings calls. Revenue guidance for FY2026? Revised downward across the sector.

Wholesale Pricing Under Pressure

Wholesale flower prices fell 12% in the past six months as domestic supply outpaced demand. Bulk dried flower now trades at AUD 4.20 per gram on average, down from AUD 4.75 in October 2025, according to industry pricing data. Import competition from lower-cost Canadian and European producers has accelerated the decline.

Gross margins for ASX cannabis operators contracted an average 340 basis points in the December 2025 quarter. Companies without vertically integrated retail channels or differentiated genetics face the steepest pressure.

Cultivation Costs Rise

Energy and labor costs climbed 9% year-over-year, eroding grower profitability. Indoor cultivation facilities in New South Wales and Victoria saw electricity expenses rise 11% in 2025 as utility rates increased, while labor costs grew 8% as the sector competed for skilled horticulturists and compliance staff.

Only operators with outdoor or greenhouse capacity maintained stable cost structures. Cann Group's outdoor facility in Victoria reported a 22% lower cost-per-gram than indoor peers.

Regulatory Tailwinds Persist

The TGA approved 38 new cannabis products in Q1 2026, the highest quarterly total on record. Approvals included five novel cannabinoid formulations and three transdermal delivery systems. Faster approval timelines and expanded therapeutic categories support long-term demand, but near-term oversupply offsets the benefit.

State-level access reforms in Queensland and South Australia added an estimated 120,000 eligible patients in 2025. Conversion rates? Still below 15%.

M&A Activity Accelerates

Three ASX cannabis companies announced merger discussions in the past 90 days as consolidation pressures mount. Little Green Pharma and Zelira Therapeutics (ASX:ZLD) confirmed exploratory talks in April 2026. Analysts expect at least two material transactions to close before year-end as smaller operators seek scale or exit.

Share prices for mid-cap ASX cannabis stocks declined an average 18% in the six months ending May 2026, dragging total market capitalization down to AUD 1.1 billion from AUD 1.8 billion at the 2025 peak.

What Investors Are Watching

Profitability timelines and cash-burn rates will determine which operators survive the margin squeeze. Companies with positive EBITDA or clear paths to breakeven by mid-2027 are trading at premiums. Those still burning AUD 2 million or more per quarter? They face dilution risk or distressed exits.

For full background on this story, see the CannIntel topic hub on Australia's medicinal cannabis market. The next catalyst: Q2 2026 earnings releases begin in late July.